Clinical Trials Browser

Recruiting × Interventional × Alpelisib × Clear all

NCT05948943 2026-04-22

EPIK-L1

Phase 2/3 Recruiting

Lymphangioma, Lymphangioma, Cystic, Lymphatic Abnormalities

NCT05564377 2026-04-21

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Phase 2 Recruiting

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT06545682 2026-04-16

Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)

Phase 1 Recruiting

BreastDermatologic

Breast Neoplasms, Melanoma

NCT05983159 2026-02-19

TARGET-VM

Phase 2 Recruiting

Arteriovenous Malformations, Lymphangioma, Skin Diseases, Vascular, Lymphangioma, Cystic, Lymphatic Abnormalities, Vascular Malformations

NCT05933395 2026-01-20

GERTRUDE

Phase 2 Recruiting

Neoplasm Metastasis

NCT05563220 2026-01-06

ELEVATE

Phase 1/2 Recruiting

Breast Neoplasms

NCT05508906 2025-10-22

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

Phase 1 Recruiting

Breast Neoplasms

NCT06739395 2024-12-18

Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion

Phase 2 Recruiting

Other solid neoplasm

Solid Tumor

NCT03631953 2024-08-06

ALTREM

Phase 1 Recruiting

Meningioma

NCT02925234 2024-01-24

DRUP

Phase 2 Recruiting

Neoplasms